Rejuvine Life Sciences Inc.

04/17/2025 | Press release | Distributed by Public on 04/17/2025 09:30

Annual Report by Private Issuer (Form C-AR)

FORM C UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB APPROVAL


FORM C-AR

OMB Number: ####-####

Estimated average burden hours per response: ##.#

Form C: Filer Information

Filer CIK:
0002008980
Filer CCC:
XXXXXXXX
File Number:
020-33995
Period:
12-31-2024


Is this a LIVE or TEST Filing? LIVE TEST
Is this an electronic copy of an official filing submitted in paper format in connection with a hardship exemption?
Would you like a Return Copy?

Submission Contact Information

Name:
Phone Number:
Contact E-Mail Address:
Notify via Filing Website only?

Form C: Issuer Information

Issuer Information

Name of Issuer:
Rejuvine Life Sciences, Inc.


Legal Status of Issuer:

Form:
Corporation


Jurisdiction of Incorporation/Organization:
DELAWARE


Date of Incorporation/Organization:
02-09-2023


Physical Address of Issuer:

Address 1:
651 North Broad Street


Address 2:
Suite 201


City:
Middletown


State/Country:
DELAWARE


Mailing Zip/Postal Code:
19709


Website of Issuer:
https://rejuvinelife.sppx.io


Form C: Offering Information

Offering Information

Form C: Annual Report Disclosure Requirements

Annual Report Disclosure Requirements

Current Number of Employees:
10


Total Assets Most Recent Fiscal Year-end:
4075294.00


Total Assets Prior Fiscal Year-end:
4205052.00


Cash and Cash Equivalents Most Recent Fiscal Year-end:
14169.00


Cash and Cash Equivalents Prior Fiscal Year-end:
30950.00


Accounts Receivable Most Recent Fiscal Year-end:
4000000.00


Accounts Receivable Prior Fiscal Year-end:
4000000.00


Short-term Debt Most Recent Fiscal Year-end:
0.00


Short-term Debt Prior Fiscal Year-end:
0.00


Long-term Debt Most Recent Fiscal Year-end:
3910000.00


Long-term Debt Prior Fiscal Year-end:
3910000.00


Revenue/Sales Most Recent Fiscal Year-end:
47234.00


Revenue/Sales Prior Fiscal Year-end:
4230.00


Cost of Goods Sold Most Recent Fiscal Year-end:
21121.00


Cost of Goods Sold Prior Fiscal Year-end:
-5076.00


Taxes Paid Most Recent Fiscal Year-end:
0.00


Taxes Paid Prior Fiscal Year-end:
17277.00


Net Income Most Recent Fiscal Year-end:
-115455.00


Net Income Prior Fiscal Year-end:
-205500.00


Form C: Signature

Signature

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.
Issuer:
Rejuvine Life Sciences, Inc.


Signature:
Theenathayalan Parthasarathy


Title:
CEO & Founder


Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature:
Theenathayalan Parthasarathy


Title:
CEO & Founder


Date:
04-17-2025